MedTrace Logo

Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients

NCT06479460 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-07-24

No results posted yet for this study

Summary

1. To explore the predictive value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population;
2. To evaluate the prognostic value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population.

Conditions

Interventions

DIAGNOSTIC_TEST

ctDNA-MRD

This study is an observational non intervention study that only tests peripheral blood samples from different treatment nodes of the subjects, without interfering with the normal clinical diagnosis and treatment process of the patients.

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-08
Primary Completion
2025-05-31
Completion
2026-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06479460 on ClinicalTrials.gov